Investors purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on weakness during trading hours on Thursday. $63.04 million flowed into the stock on the tick-up and $35.59 million flowed out of the stock on the tick-down, for a money net flow of $27.45 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 27th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($0.45) for the day and closed at $107.60

Several research analysts have weighed in on ALXN shares. Royal Bank Of Canada upped their target price on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. SunTrust Banks, Inc. restated a “buy” rating and set a $180.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. BidaskClub lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Deutsche Bank AG restated a “buy” rating and set a $158.00 target price (up from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Leerink Swann reiterated a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $154.01.

The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The firm has a market cap of $24,038.87, a P/E ratio of 22.00, a PEG ratio of 1.17 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 earnings per share. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year.

In related news, EVP Julie O’neill sold 4,375 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the transaction, the executive vice president now owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ann M. Veneman sold 835 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock worth $2,337,251 in the last three months. Insiders own 4.35% of the company’s stock.

Large investors have recently bought and sold shares of the business. Fiduciary Trust Co. purchased a new position in Alexion Pharmaceuticals during the second quarter worth approximately $111,000. Valeo Financial Advisors LLC purchased a new position in Alexion Pharmaceuticals during the third quarter worth approximately $147,000. Huntington National Bank raised its stake in Alexion Pharmaceuticals by 1,084.6% during the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 987 shares during the period. Dupont Capital Management Corp purchased a new position in Alexion Pharmaceuticals during the third quarter worth approximately $156,000. Finally, BT Investment Management Ltd purchased a new position in Alexion Pharmaceuticals during the third quarter worth approximately $165,000. 95.80% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Traders Buy Alexion Pharmaceuticals, Inc. (ALXN) on Weakness” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/traders-buy-alexion-pharmaceuticals-inc-alxn-on-weakness/1725372.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.